9464 - National Contract for Direct Acting Antiviral Medicines for GT3 Treatment in Hep C Programme
The RFT has ended, you cannot answer the invitation.
The HSE wishes to establish a national Contract for directly acting antiviral medicines for the treatment of Hepatitis C Genotype 3 Infection (or other genotypes where a genotype 3 regimen is suitable) for use in provision of treatment to a limited number of GT3 patients to the end of 2017.
This tender process is a once off to cover patients initiating treatment with GT3 regimen up to 31st December 2017.